Abstract:Background Liver targeting drug delivery systems can improve the curative effects and relieve the cytotoxicity of the chemotherapy drugs in the treatment of liver diseases. Nanoparticles carrying therapeutic drugs are currently under hot investigation with great clinical significance. This study was aimed to investigate the different tissue distribution of the adriamycin polybutylcyanoacrylate nanoparticle (ADM-PBCA-NP) in the mice body after an injection via lateral tail vein, and to study the liver targeting effects of ADM-PBCA-NP in different diameters on normal mice liver.Methods One hundred and eighty Kunming mice were randomly divided into 6 groups with 30 mice in each group (5 treatment groups of ADM-PBCA-NP in the different diameter ranges, non-conjugated free adriamycin injection was employed as the control group). A single dose of either conjugated or free adriamycin equaled 2 mg/kg of body weight was delivered via the tail vein. Five mice in each trail were sacrificed at 5, 15, 30 minutes, 1, 5 and 12 hours postinjection, respectively. The adriamycin concentrations in the respectively collected liver, kidney, spleen, heart, lung and plasma were demonstrated using a high performance liquid chromatography with fluorescence detector.Results Compared with the control group, adriamycin was hardly detected in the heart muscle of the treatment groups (P < 0.05). The nanoparticle-conjugated adriamycin was cleaned up quickly from the kidney tissue. The adriamycin concentrations of the mice liver and spleen in the experimental groups were significantly higher than that in the control group, except for the group with the nanoparticles diameters of (22.3 +/- 6.2) nm (P < 0.05). The ADM-PBCA-NP in (101.0 +/- 20.3) nm diameter had the highest liver distribution, and the second highest adriamycin distribution in liver was the group of (143.0 +/- 23.5) nm diameter (P < 0.05). Moreover, adriamycin was released slowly in the liver during the detection period in the experimental groups. ADM-PBCA-NP in (22.3 +/- 6.2) nm diameter was not distributed in the tissue of the liver, kidney, heart, spleen, and lung.Conclusions ADM-PBCA-NP in 100-150 nm diameter range has the best liver targeting with a characteristic of slow medicine release. It also decreases the medicine distribution in the heart, kidney and lung. In the treatment of liver cancer, the polybutylcyanoacrylate, nanoparticles system has a good liver targeting ability, which increases the anticancer activity and markedly decreases the toxicity of adriamycin.

Preparation of oxymatrine n-butyl polycyanoacrylate nanoparticles and its hepatoprotective effects in ob/ob mice

A proteomics-based study of the mechanism of oxymatrine to ameliorate hepatic fibrosis in mice

Oxymatrine alleviates high-fat diet/streptozotocin-induced non-alcoholic fatty liver disease in C57BL/6 J mice by modulating oxidative stress, inflammation and fibrosis

Liver Targeting and the Delayed Drug Release of the Nanoparticles of Adriamycin Polybutylcyanoacrylate in Mice

Oxymatrine Induces Liver Injury Through JNK Signalling Pathway Mediated by TNF‐α in Vivo

Bile acid-based polydrug nanoparticles for the treatment of acute liver injury

Cyclic RGD-peptide-modified Nanoliposome Significantly Reduced the Effective Dosage and Administration Frequency of Oxymatrine on CCl4-induced Hepatic Fibrosis in Rats

Preclinical Validation of Silibinin/albumin Nanoparticles As an Applicable System Against Acute Liver Injury.

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice

Effects of Oxymatrine on Experimental Hepatic Fibrosis and Its Mechanism in Vivo

Oxymatrine Causes Hepatotoxicity by Promoting the Phosphorylation of JNK and Induction of Endoplasmic Reticulum Stress Mediated by ROS in LO2 Cells

Protective effects of oleanolic acid on acetaminophen-induced hepatotoxicity in mice.

Propitious maneuvering for delivery of the phytopharmaceutical "apocynin" to induced fulminant hepatitis in BALB/c mice: In vitro and in vivo assessments

Reparative Efficacy of Liposome-Encapsulated Oleanolic Acid against Liver Inflammation Induced by Fine Ambient Particulate Matter and Alcohol in Mice

A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment

Protective Effects of Oxymatrine Against Arsenic Trioxide-Induced Liver Injury

A Clinical Research on Oxymatrine for the Treatment of Chronic Hepatitis B

Nomilin and its analogue obacunone alleviate NASH and hepatic fibrosis in mice via enhancing antioxidant and anti-inflammation capacity

Preparation of a nanoemulsified drug delivery system of astilbin using edible formulation components: In vivo evaluation of oxaliplatin-induced cirrhotic liver injury

Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of oxymatrine

Oxymatrine Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice Via the Inhibition of Inducible Nitric Oxide Synthase Expression and the TGF-β/Smad Signaling Pathway.